STRADEFY BIOSCIENCES


Associated tags: IND, Nanoparticle, Yale University, Science, Genzyme, Physician, MIT, Cornell University, MBA, Chemical engineering, Business operations, Therapy, Patient, Proteostasis, Pharmaceutical industry

Stradefy Biosciences Appoints Jeffrey M. Goldberg as Executive Chair

Retrieved on: 
Tuesday, December 19, 2023
Yale University, Science, Genzyme, Physician, MIT, Cornell University, MBA, Chemical engineering, Business operations, Therapy, Patient, Proteostasis, Pharmaceutical industry

NEW HAVEN, Conn., Dec. 19, 2023 /PRNewswire-PRWeb/ -- Stradefy Biosciences, a New Haven-based drug discovery and development company based on Yale University research, today announced the appointment of Jeffrey M. Goldberg as Executive Chair, effective immediately. Mr. Goldberg is an accomplished biotech executive with over 25 years of experience leading teams from preclinical discovery through commercialization. He previously served as President and Chief Executive Officer of both Immunitas Therapeutics and Aeglea Biotherapeutics, now Spyre Therapeutics.

Key Points: 
  • NEW HAVEN, Conn., Dec. 19, 2023 /PRNewswire-PRWeb/ -- Stradefy Biosciences , a New Haven-based drug discovery and development company based on Yale University research, today announced the appointment of Jeffrey M. Goldberg as Executive Chair, effective immediately.
  • Mr. Goldberg is an accomplished biotech executive with over 25 years of experience leading teams from preclinical discovery through commercialization.
  • He previously served as President and Chief Executive Officer of both Immunitas Therapeutics and Aeglea Biotherapeutics, now Spyre Therapeutics .
  • "I'm incredibly excited to be joining Stradefy and helping to facilitate the development of new technologies for patients battling devastating diseases," said Mr. Goldberg.